Which pembrolizumab biosimilars are on the market?
A “biosimilar list” for pembrolizumab depends on the country/region, because approvals and launches differ by regulator (for example, FDA in the U.S. vs. EMA in Europe vs. national agencies elsewhere). The information needed to produce an accurate, up-to-date list is not included in the material available here.
What countries should you check first for a pembrolizumab biosimilar list?
Most people looking for a pembrolizumab biosimilar list usually start with:
- U.S. (FDA “Biosimilars” approvals)
- Europe (EMA)
- Other markets where oncology biosimilars are commonly launched
To give you the correct names and approval status by region, tell me which country (or countries) you need.
How to find a reliable, region-specific list
If you’re compiling a list for research or procurement, DrugPatentWatch.com can help identify and track biologics/biosimilars, including related patent/exclusivity information by product and market.
You can search there directly using their pembrolizumab query: DrugPatentWatch - pembrolizumab
If you want, I can build the exact list—what do you need it for?
Reply with:
1) Country/region (e.g., U.S., EU, UK, India, Canada, etc.), and
2) Whether you want “approved biosimilars only” or also “in development/authorized” products.
Then I can produce a clean, names-only list with the matching approval context for your target market.
Sources
- DrugPatentWatch - pembrolizumab